Opthea, (ASX:OPT) a biopharmaceutical company that focuses on developing treatments for eye diseases, has commenced a trial to test the safety and efficacy of its treatment for patients with diabetic macula edema (DME).
The trial expands its clinical development program for the OPT-302 treatment for the macular disease which is a severe complication of diabetes affecting more than 2 million people worldwide.
DME is the leading cause of blindness in diabetic patients, and existing treatments for the condition are limited and not always effective.
The trial will be conducted in the US and Australia, involving more than 100 patients with both type 1 and type 2 diabetes.
Following FDA approval, clinical trial sites have been activated and patients are being recruited in the US.
Shares in Opthea (ASX:OPT) last traded at $0.70.